Early Termination Strategies When Risk Benefit No Longer Supports Continuation Early Termination Strategies When Risk Benefit No Longer Supports Continuation In the complex landscape of pharmaceutical development, the ability to make informed go/no-go decisions is crucial. These decisions dictate whether a drug candidate continues through the pipeline, moving from preclinical phases to clinical testing, and ultimately to market launch. However, there may come a time when the risk-benefit profile of a candidate no longer supports its continuation. This article explores early termination strategies, with a focus on regulatory compliance and institutional frameworks that can guide pharma professionals in effectively managing…

Governance Models for Cross Functional Portfolio Review Committees Governance Models for Cross Functional Portfolio Review Committees The pharmaceutical industry operates in a complex regulatory environment characterized by stringent guidelines and evolving market dynamics. Governance models for cross-functional portfolio review committees are essential for ensuring effective decision-making in drug development processes. These models are particularly relevant in the context of Go/No-Go Decision criteria, which serve as crucial checkpoints in the Research and Development (R&D) lifecycle. This article provides an in-depth exploration of governance models, with insights aligned to FDA, EMA, and MHRA expectations. Understanding Go/No-Go Decision Criteria Go/No-Go decision criteria are…

Scenario Analysis for Regulatory Delays, CRLs, and Competitive Launches Scenario Analysis for Regulatory Delays, CRLs, and Competitive Launches In the evolving landscape of pharmaceutical development, understanding the nuances of scenario analysis becomes critical in managing risks associated with regulatory delays, complete response letters (CRLs), and competitive product launches. Successful drug development requires comprehensive evaluation methodologies, including go/no-go decision criteria, which help teams assess the viability of various projects. This article serves as a guide for pharma professionals, clinical operations, regulatory affairs, and medical affairs experts navigating the complexities of the regulatory landscape driven by the standards set forth by the…

Board Level Communication of Key Go No Go and Portfolio Decisions Board Level Communication of Key Go No Go and Portfolio Decisions In the complex landscape of drug development, the board’s ability to efficiently navigate go no go decision criteria, assess risks, and prioritize a robust R&D portfolio is paramount. This article aims to guide pharmaceutical professionals through the nuances of communicating key portfolio decisions at the board level, taking into account the expectations set forth by regulatory bodies such as the FDA, EMA, and MHRA. Understanding Go No Go Decisions and Enrollment Criteria The concept of a go no…

Risk registers and mitigation plans at asset and portfolio levels Risk registers and mitigation plans at asset and portfolio levels In today’s fast-paced pharmaceutical landscape, effective risk management is crucial for success across asset and portfolio levels. This article provides a comprehensive overview of how to utilize risk registers and develop mitigation plans that align with the regulatory frameworks of the FDA, EMA, and MHRA. Professionals in clinical operations, regulatory affairs, and medical affairs need to understand how to navigate these complex requirements while ensuring that their strategies facilitate better go/no-go decisions and optimized resource allocation. The Importance of Go/No-Go…

Linking Go/No-Go Decisions to Resource Allocation and Functional Budgets Linking Go/No-Go Decisions to Resource Allocation and Functional Budgets The pharmaceutical industry is characterized by high uncertainty and significant capital investment. As such, the go/no-go decision-making process plays a critical role in the development of new therapeutics, determining how resources are allocated and ensuring that budgets are functionally aligned with strategic objectives. This article will provide an in-depth exploration of how to effectively link go/no-go decision criteria to resource allocation and functional budgets within the context of regulatory frameworks, including those set forth by the FDA, EMA, and MHRA. Understanding Go/No-Go…

Portfolio Planning for Small Biotech vs Large Pharma: What Differs in Practice Portfolio Planning for Small Biotech vs Large Pharma: What Differs in Practice Effective portfolio planning is a crucial aspect of the pharmaceutical industry that directly impacts the success rates of drug development initiatives. The distinct operational paradigms of small biotech firms and large pharmaceutical companies lead to varying approaches in portfolio management, particularly when evaluating go/no-go decision criteria. This article explores those differences in detail, emphasizing regulatory frameworks such as the FDA’s Federal Food, Drug, and Cosmetic Act (FD&C Act), EMA guidelines, and ICH recommendations to provide a…

Tools for Visualising Portfolio Balance, Risk Concentration and Geographic Spread Tools for Visualising Portfolio Balance, Risk Concentration and Geographic Spread The pharmaceutical landscape is characterized by dynamic changes in regulatory environments, increasing competition, and rapid technological advancements. Effective drug development strategies become imperative for navigating these complexities. Essential tools that facilitate visualisation of portfolio balance, risk concentration, and geographic spread empower pharma professionals to make informed, strategic decisions while adhering to regulatory guidelines. Understanding Go/No-Go Decision Criteria The Go/No-Go decision-making process is integral to drug development, especially during critical transition phases such as clinical trials. The decision criteria established in…

Future of Portfolio Management Data Platforms, AI Scoring and Dynamic Reprioritisation Future of Portfolio Management Data Platforms, AI Scoring and Dynamic Reprioritisation In the dynamic environment of pharmaceutical development, the structures that define portfolio management have undergone tremendous transformations. As regulatory frameworks evolve, so too must the methodologies employed by pharmaceutical managers and strategic decision-makers. This article explores essential elements that encompass go/no-go decision criteria, pharma portfolio risk management, and R&D portfolio prioritisation, offering insights into future trends driven by advanced technologies such as Artificial Intelligence (AI) and big data analytics. Understanding Go/No-Go Decision Criteria The go/no-go decision criteria are…

Embedding Lessons Learned from Past Portfolio Decisions into New Governance Embedding Lessons Learned from Past Portfolio Decisions into New Governance The pharmaceutical industry is characterized by uncertainty and risk, particularly in drug development. To navigate this complexity, companies must consider a structured approach to decision-making, especially during the Go/No-Go junctures in their product portfolios. This article discusses how embedding lessons learned from past portfolio decisions can enhance governance frameworks, focusing on the criteria for Go/No-Go decisions, risk management techniques, the role of advanced technologies, and the importance of effective communication with stakeholders. The Importance of Go/No-Go Decision Criteria in Pharma…